KCNJ2 Gene Short QT Syndrome Type 3 NGS Genetic DNA Test
Understanding Short QT Syndrome Type 3
Short QT Syndrome Type 3 is a rare inherited cardiac channelopathy characterized by abnormally shortened QT intervals on electrocardiograms, predisposing individuals to life-threatening arrhythmias and sudden cardiac death. This condition results from mutations in the KCNJ2 gene, which encodes the inward rectifier potassium channel Kir2.1, playing a crucial role in cardiac repolarization and maintaining electrical stability in the heart.
What Does This Test Measure?
Our advanced Next-Generation Sequencing (NGS) technology comprehensively analyzes the KCNJ2 gene to identify pathogenic variants associated with Short QT Syndrome Type 3. The test detects:
- Point mutations in the KCNJ2 gene coding regions
- Small insertions and deletions affecting gene function
- Genetic variants that alter potassium channel kinetics
- Inherited mutations causing abnormal cardiac repolarization
Who Should Consider This Test?
Clinical Indications and Symptoms
This genetic test is recommended for individuals presenting with:
- Unexplained syncope or fainting episodes
- Palpitations or irregular heart rhythms
- Family history of sudden cardiac death
- Short QT interval on electrocardiogram (<340 ms)
- Atrial fibrillation at a young age
- Unexplained seizures or cardiac arrest
- Family members of diagnosed Short QT Syndrome patients
Benefits of Genetic Testing
Undergoing the KCNJ2 genetic test provides numerous advantages:
- Accurate Diagnosis: Confirms or rules out Short QT Syndrome Type 3
- Personalized Treatment: Guides appropriate antiarrhythmic therapy
- Family Screening: Identifies at-risk relatives for preventive care
- Risk Stratification: Helps determine need for implantable cardioverter-defibrillator
- Reproductive Planning: Provides information for family planning decisions
- Peace of Mind: Reduces uncertainty about cardiac symptoms
Understanding Your Test Results
Interpretation Guidelines
Your genetic test results will fall into one of these categories:
- Positive Result: A pathogenic variant in KCNJ2 gene is identified, confirming diagnosis of Short QT Syndrome Type 3. Comprehensive cardiac evaluation and family screening are recommended.
- Negative Result: No disease-causing variants detected in KCNJ2 gene. Other causes for symptoms should be investigated.
- Variant of Uncertain Significance: A genetic change is found, but its clinical significance is unknown. Additional family studies may be needed.
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | KCNJ2 Gene Short QT Syndrome Type 3 NGS Genetic DNA Test |
| Regular Price | $700 USD |
| Discount Price | $500 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Testing Method | Next-Generation Sequencing (NGS) Technology |
Pre-Test Requirements
Before scheduling your test, please ensure:
- Complete clinical history documentation
- Genetic counseling session to create family pedigree chart
- Discussion of test implications with healthcare provider
- Informed consent for genetic testing
Nationwide Availability
We have diagnostic centers across the United States, serving patients in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art laboratories ensure consistent, high-quality genetic testing nationwide.
Take Action for Your Cardiac Health
Don’t let uncertainty about cardiac symptoms affect your quality of life. Early detection of Short QT Syndrome Type 3 can be life-saving. Our expert team of cardiologists and genetic specialists are ready to provide comprehensive care and guidance.
Book your KCNJ2 Genetic Test today by calling +1(267) 388-9828 or schedule your appointment online. Take the first step toward understanding your cardiac health and protecting your future.
